Develops cancer immunotherapies that selectively activate within tumors.
Jun 2026Revenue $64.1M/yrExpenses $95.5M/yr
No trendCash runway ≈ 2.2 years from Jun 2026
Figures by year
When will Xilio Therapeutics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $64.1M and expenses $95.5M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $43.8M | $85.7M | −$42.0M |
| Dec 2024 | $6.34M | $66.9M | −$60.6M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.